DelveInsight’s “Interstitial Lung Diseases Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Diseases pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Interstitial Lung Diseases Pipeline. Dive into DelveInsight’s comprehensive report today! @ Interstitial Lung Diseases Pipeline Outlook

Key Takeaways from the Interstitial Lung Diseases Pipeline Report

• In July 2025, Boehringer Ingelheim announced a study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are between 6 and 17 years old (in France, between 12 and 17 years old) and have fibrosing ILD.
• In July 2025, United Therapeutics announced a study RIN-PF-305 is a Phase 3, multinational, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of inhaled treprostinil in subjects with PPF over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID.
• In July 2025, GlaxoSmithKline conducted a study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
• In July 2025, Bristol-Myers Squibb organized a study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
• In July 2025, Genentech Inc. announced a study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
• In July 2025, Mediar Therapeutics conducted a study’s inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to receive MTX-463 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved IPF therapies, pifenidone or nintedanib, is permitted, and it is expected that about half the study population will be on one of those medications. Participants randomized to the MTX-463 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20.
• DelveInsight’s Interstitial Lung Diseases Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
• The leading Interstitial Lung Diseases Companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
• Promising Interstitial Lung Diseases Pipeline Therapies such as Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev®), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.

Stay ahead with the most recent pipeline outlook for Interstitial Lung Diseases. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Interstitial Lung Diseases Treatment Drugs

Interstitial Lung Diseases Emerging Drugs Profile

• DWN12088: Daewoong Pharmaceutical

DWN12088 is an investigational therapy for idiopathic Interstitial Lung Diseases (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic Interstitial Lung Diseases (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

• LYT-100: PureTech

LYT-100 is PureTech’s most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.

• BMS-986278: Bristol-Myers Squibb

BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic Interstitial Lung Diseases. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.

The Interstitial Lung Diseases Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Diseases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Diseases Treatment.
• Interstitial Lung Diseases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interstitial Lung Diseases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Diseases market

Explore groundbreaking therapies and clinical trials in the Interstitial Lung Diseases Pipeline. Access DelveInsight’s detailed report now! @ New Interstitial Lung Diseases Drugs

Interstitial Lung Diseases Companies

Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Interstitial Lung Diseases Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Interstitial Lung Diseases Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Interstitial Lung Diseases Market Drivers and Barriers

Scope of the Interstitial Lung Diseases Pipeline Report

• Coverage- Global
• Interstitial Lung Diseases Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences and others.
• Interstitial Lung Diseases Pipeline Therapies- Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev®), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide and others.
• Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Interstitial Lung Diseases Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Interstitial Lung Diseases Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Interstitial Lung Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Interstitial Lung Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RO-0220912: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Daratumumab: Janssen Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BGB 16673: BeiGene
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Inactive Products
19. Interstitial Lung Disease Key Companies
20. Interstitial Lung Disease Key Products
21. Interstitial Lung Disease- Unmet Needs
22. Interstitial Lung Disease- Market Drivers and Barriers
23. Interstitial Lung Disease- Future Perspectives and Conclusion
24. Interstitial Lung Disease Analyst Views
25. Interstitial Lung Disease Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight